ClinicalTrials.gg
CompletedNCT00423891Updated May 2, 2018Results posted

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

A Phase 1/2 interventional study of Entecavir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 19 sites in 8 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-05-02.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
42nd of 61
64 · median 109
Started
2007
with 6 others
Phase 1/2
Only one
of the 64
Registered
10th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 42nd largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2007, is the only one in phase 1/2, and was the 10th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this clinical study is to determine the appropriate doses of entecavir to use in children and adolescents. Safety, tolerability and efficacy will also be studied

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 2-18 years of age
  • Group A: Lamivudine naive (\<1 week of Lamivudine) and not within 24 weeks of screening; Group B: Lamivudine experienced (> 12 weeks of Lamivudine); Group C: nucleoside/nucleotide experienced (> 12 weeks of nucleoside/tide therapy) added as a country-specific protocol amendment (not all sites had Group C).
  • Deoxyribonucleic acid (DNA) ≥ 100000 copies/mL; ≥ 10000 copies for nucleoside/nucleotide experienced (Group C)
  • Detectable Hepatitis B surface antigen (HBsAg) for 24 weeks prior to screening
  • Hepatitis B e antigen (HBeAg) positive
  • Compensated liver and renal function
  • Elevated (ALT) at screening and during the 24 weeks prior to screening (for Groups A and B)

Exclusion criteria

Exclusion Criteria:

  • Coinfection with (HIV), virus (HCV), Hepatitis D Virus (HDV)
  • Children who were breastfed while their mother received Lamivudine, or children whose mothers received Lamivudine during pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Arm 1: Entecavir

    Drug: Entecavir

Interventions

  • Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response

    Also known as: Baraclude, BMS-200475

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Medical Dictionary for Regulatory Activities (MedDRA) version 16.0 was used.

    Time frame: Day 1 to Week 120

Secondary outcomes

  1. Mean Maximum Observed Plasma Concentration (Cmax) and Mean Trough Observed Plasma Concentration (Cmin) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort

    Cmax and Cmin were derived from plasma concentration of ETV versus time and measured in nanograms per milliliters (ng/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Note: PK parameters were summarized for only Groups A and B. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.

    Time frame: Day 14

  2. Median Time of Maximum Observed Plasma Concentration (Tmax) in LVD-naive and LVD-experienced Participants, by Age Cohort

    Tmax was derived from plasma concentration of ETV versus time and measured in hours (h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Age categories presented below: participants age as of first day of dosing. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.

    Time frame: Day 14

  3. Mean Area Under the Concentration-Time Curve in One Dosing Interval [AUC(TAU)] of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort

    Area under the Curve (AUC) was derived from plasma concentration of ETV versus time. AUC(TAU) was calculated by log- and linear trapezoidal summations, TAU = 24 hours, and was measured in nanograms\*hours per milliliter (ng\*h/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.

    Time frame: Day 14

  4. Mean Apparent Total Body Clearance (CLT/F) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort

    CLT/F was calculated by dividing the dose of ETV by AUC(TAU) of ETV and was measured in liters per hour (L/h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.

    Time frame: At 2 weeks

  5. Number of Participants With HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants

    Hepatitis B virus DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS TaqMan - high pure system (HPS) assay and was reported in international units per milliliter (IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline to Week 96

  6. Number of Participants With Hepatitis B e Antigen (HBeAg) Loss Through Week 96 in Treated Participants

    HBeAg loss: HBeAg negative. The method used for the detection of HBe Ag was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline to Week 96

  7. Number of Participants With Hepatitis B s Antigen (HBsAg) Loss Through Week 96 in Treated Participants

    HBsAg loss: HBsAg negative. The method used for detection of HBsAg was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline to Week 96

  8. Number of Participants With Hepatitis B e Antigen Seroconversion Through Week 96 in Treated Participants

    HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HB e antibodies (HBeAb), ie both the presence of HBeAb and the absence of HBeAg. The method used for the detection HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline through Week 96

  9. Number of Participants With HBV DNA Less Than Lower Limit of Detection (LLD) for the Roche COBAS TaqMan - HPS Assay at Week 96 in Treated Participants

    Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLD = 6 IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline to Week 96

  10. Number of Participants With HBV DNA Less Than Lower Limit of Quantification (LLQ) for the Roche COBAS TaqMan - HPS Assay Through Week 96 in Treated Participants

    Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline through Week 96

  11. Number of Participants With HB s Antigen (HBsAg) Seroconversion Through Week 96 in Treated Participants

    HB s Ag seroconversion: loss of HBsAg (HBsAg negative) and presence of HB s antibodies (HBsAb). The method used for the detection of HBsAg seroconversion was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline through Week 96

  12. Number of Participants Who Had a Protocol Defined Response (PDR) Through Week 96 in Treated Participants

    PDR was defined as confirmed HBV DNA \< 50 IU/mL plus confirmed HBeAg seroconversion on 2 sequential measurements at least 14 days apart. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline to Week 96

  13. Mean Log10 Change From Baseline in HBV DNA Using Roche COBAS TaqMan - HPS Through Week 96 in Treated Participants

    Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. HBV DNA log10 changes from baseline were summarized over time.

    Time frame: Baseline to Week 96

  14. Alanine Aminotransferase (ALT) Normalization From Baseline Through Week 96 in Treated Participants

    Normalization in ALT= ALT ≤ 1.0\*upper limit of normal (ULN). Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline to Week 96

  15. Number of Participants With HBV DNA by PCR Categories at Weeks 48 and 96 in Treated Participants

    Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

    Time frame: Baseline, Week 48, Week 96

  16. Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants

    Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN.

    Time frame: Baseline to Week 96

  17. Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Plus HBeAg Seroconversion Through Week 96 in Treated Participants

    Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion was determination of presence of HBeAb and loss of HBeAg. The method used for the detection of HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit.

    Time frame: Baseline to Week 96

  18. Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Without HBeAg Seroconversion, Through Week 96 in Treated Participants

    Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HBeAb. The method used for the detection of HBeAg/Ab serologies was the DiaSorin enzyme immunoassay kit.

    Time frame: Baseline to Week 96

  19. Number of Participants With Hematology Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants

    Toxicity Scale: Division of AIDs (DAIDS) grades Version 1.0. Upper limit of normal (ULN); lower limit of normal (LLN); Cells per Liter (c/L); cells per microliter (c/µL); grams per deciliter (g/dL); milliequivalents per liter (mEq/L); cells per microliter (c/µL): Grade (Gr). Hemoglobin g/dL: Gr1:10.0-10.9;Gr2: 9.0-9.9; Gr3:7.0-8.9; Gr4: \<7.0. International normalization ratio (INR): Gr1:1.1-\<1.5\*ULN; Gr2: 1.6-\<2.0\*ULN; Gr3: 2.1-3.0\*ULN;Gr4: \>3.0\*ULN. Neutrophils/bands c/µL: Gr1;1.0-1.3\*10\^3; Gr2: 0.75-0.99\*10\^3; Gr 3: 0.50-0.749\*10\^3; Gr4: \<0.5\*10\^3.

    Time frame: Day 1 to Week 120

  20. Number of Participants With Chemistry Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants

    Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO). Grade (Gr). ALT: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0 \*ULN; Gr3: 5.1-10.0\*ULN; Gr4:\>10.0\*ULN. Aspartate aminotransferase (AST): Gr1: 1.25-\<2.5\*ULN; Gr2:2.6-\<5.0\*ULN; Gr 3: 5.1-10.0\*ULN; Gr4\>10.0\*ULN. Alkaline phosphatase: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0\*ULN; Gr3: 5.1-10.0\*ULN; Gr4: \>10.0\*ULN. Lipase: Gr1:1.1-\<1.5\*ULN;Gr2:1.6-\<3.0\*ULN; Gr3: 3.1-5.0\*ULN; Gr4: \>5.0\*ULN. Creatinine: Gr1: 1.1-1.3\*ULN; Gr2: 1.4-\<1.8\*ULN; Gr3: 1.9 - \<3.4\*ULN; Gr4: \>=3.5\*ULN. Glucose mg/dL (high): Gr1:110-\<125 (Fasting)/116-\<160;Gr2:126-\<250 (F)/161-\<250; Gr3: 251-500; Gr4: \>500.Glucose (low): Gr1: 55-64; Gr2: 40 - \<54; Gr3: 30-39; Gr4: \<30 mg/dL.

    Time frame: Day 1 to Week 120

  21. Number of Participants With Electrolyte Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants

    Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO) for chloride. Milliequivalents per liter (mEq/L); Grade (Gr). Chloride high (mEq/L): Gr1: 113-\<117; Gr2: 117-\<121; Gr3: 121-125; Gr4: \>125. Potassium low (mEq/L): Gr1: 3.0-3.4; Gr2: 2.5-2.9; Gr3:2.0-\<2.4; Gr4: \<2.0. Potassium high: Gr1; 5.6- \<6.0; Gr2: 6.1-\<6.5; Gr3: 6.6-7.0; Gr4: \>7.0. Sodium high (mEq/L): Gr1; 146-\<150; Gr2: 151-\<154; Gr3: 155-\<159; Gr4: \>=160.

    Time frame: Day 1 Week 120

07

Results

Posted Aug 7, 2014

Participant flow

Enrolled
Participant flow — Enrolled
MilestoneLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Started35218
Completed24195
Not completed1123
Withdrew: Withdrawal by subject001
Withdrew: Lost to follow-up001
Withdrew: No longer met criteria1121
Treatment
Participant flow — Treatment
MilestoneLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Started24195
Completed22195
Not completed200
Withdrew: Withdrawal by subject100
Withdrew: Lost to follow-up100
Post-Dosing Follow Up
Participant flow — Post-Dosing Follow Up
MilestoneLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Started22185
Completed20153
Not completed232
Withdrew: Withdrawal by subject032
Withdrew: Lost to follow-up200

Outcome measures

SecondaryMean Maximum Observed Plasma Concentration (Cmax) and Mean Trough Observed Plasma Concentration (Cmin) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort

Cmax and Cmin were derived from plasma concentration of ETV versus time and measured in nanograms per milliliters (ng/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Note: PK parameters were summarized for only Groups A and B. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.

Time frame:
Day 14
Reported as:
Geometric mean · ng/mL
Mean Maximum Observed Plasma Concentration (Cmax) and Mean Trough Observed Plasma Concentration (Cmin) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
ng/mLLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)
Cmax of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3)8.07 ± 2416.03 ± 8
Cmax of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7)6.29 ± 2519.01 ± 15
Cmax of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9)5.11 ± 2711.32 ± 37
Cmin of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3)0.244 ± 320.468 ± 17
Cmin of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7)0.320 ± 220.497 ± 32
Cmin of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9)0.271 ± 250.455 ± 25
SecondaryMedian Time of Maximum Observed Plasma Concentration (Tmax) in LVD-naive and LVD-experienced Participants, by Age Cohort

Tmax was derived from plasma concentration of ETV versus time and measured in hours (h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Age categories presented below: participants age as of first day of dosing. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.

Time frame:
Day 14
Reported as:
Median · h
Median Time of Maximum Observed Plasma Concentration (Tmax) in LVD-naive and LVD-experienced Participants, by Age Cohort
hLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)
Tmax of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3)0.50 (0.5 to 1.0)1.00 (0.5 to 1.5)
Tmax of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7)0.57 (0.5 to 2.0)0.72 (0.5 to 1.0)
Tmax of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9)0.78 (0.5 to 1.0)0.52 (0.5 to 1.0)
SecondaryMean Area Under the Concentration-Time Curve in One Dosing Interval [AUC(TAU)] of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort

Area under the Curve (AUC) was derived from plasma concentration of ETV versus time. AUC(TAU) was calculated by log- and linear trapezoidal summations, TAU = 24 hours, and was measured in nanograms\*hours per milliliter (ng\*h/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.

Time frame:
Day 14
Reported as:
Geometric mean · ng*h/mL
Mean Area Under the Concentration-Time Curve in One Dosing Interval [AUC(TAU)] of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
ng*h/mLLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)
AUC(TAU) of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3)18.69 ± 2142.26 ± 27
AUC(TAU) of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7)20.42 ± 2041.50 ± 21
AUC(TAU) of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9)15.96 ± 2235.36 ± 24
SecondaryMean Apparent Total Body Clearance (CLT/F) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort

CLT/F was calculated by dividing the dose of ETV by AUC(TAU) of ETV and was measured in liters per hour (L/h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.

Time frame:
At 2 weeks
Reported as:
Mean · L/h
Mean Apparent Total Body Clearance (CLT/F) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
L/hLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)
CLT/F of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3)11.40 ± 2.56412.31 ± 3.102
CLT/F of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7)22.66 ± 6.13421.67 ± 6.940
CLT/F of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9)31.92 ± 6.42928.95 ± 6.496
SecondaryNumber of Participants With HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants

Hepatitis B virus DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS TaqMan - high pure system (HPS) assay and was reported in international units per milliliter (IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants With HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12100
Week 241030
Week 361160
Week 481490
Week 968112
SecondaryNumber of Participants With Hepatitis B e Antigen (HBeAg) Loss Through Week 96 in Treated Participants

HBeAg loss: HBeAg negative. The method used for the detection of HBe Ag was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants With Hepatitis B e Antigen (HBeAg) Loss Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12300
Week 24410
Week 36510
Week 481030
Week 96520
SecondaryNumber of Participants With Hepatitis B s Antigen (HBsAg) Loss Through Week 96 in Treated Participants

HBsAg loss: HBsAg negative. The method used for detection of HBsAg was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants With Hepatitis B s Antigen (HBsAg) Loss Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12000
Week 24000
Week 36100
Week 48100
Week 96000
SecondaryNumber of Participants With Hepatitis B e Antigen Seroconversion Through Week 96 in Treated Participants

HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HB e antibodies (HBeAb), ie both the presence of HBeAb and the absence of HBeAg. The method used for the detection HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline through Week 96
Reported as:
Number · participants
Number of Participants With Hepatitis B e Antigen Seroconversion Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12300
Week 24410
Week 36510
Week 481030
Week 96510
PrimaryNumber of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Medical Dictionary for Regulatory Activities (MedDRA) version 16.0 was used.

Time frame:
Day 1 to Week 120
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Serious Adverse Events (n=24, 19, 5)200
Discontinuations Due to AEs (n=24,19,5)000
SecondaryNumber of Participants With HBV DNA Less Than Lower Limit of Detection (LLD) for the Roche COBAS TaqMan - HPS Assay at Week 96 in Treated Participants

Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLD = 6 IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants With HBV DNA Less Than Lower Limit of Detection (LLD) for the Roche COBAS TaqMan - HPS Assay at Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12100
Week 24610
Week 36750
Week 481360
Week 96881
SecondaryNumber of Participants With HBV DNA Less Than Lower Limit of Quantification (LLQ) for the Roche COBAS TaqMan - HPS Assay Through Week 96 in Treated Participants

Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline through Week 96
Reported as:
Number · participants
Number of Participants With HBV DNA Less Than Lower Limit of Quantification (LLQ) for the Roche COBAS TaqMan - HPS Assay Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12100
Week 24920
Week 361050
Week 481470
Week 96882
SecondaryNumber of Participants With HB s Antigen (HBsAg) Seroconversion Through Week 96 in Treated Participants

HB s Ag seroconversion: loss of HBsAg (HBsAg negative) and presence of HB s antibodies (HBsAb). The method used for the detection of HBsAg seroconversion was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline through Week 96
Reported as:
Number · participants
Number of Participants With HB s Antigen (HBsAg) Seroconversion Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12000
Week 24000
Week 36000
Week 48000
Week 96000
SecondaryNumber of Participants Who Had a Protocol Defined Response (PDR) Through Week 96 in Treated Participants

PDR was defined as confirmed HBV DNA \< 50 IU/mL plus confirmed HBeAg seroconversion on 2 sequential measurements at least 14 days apart. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants Who Had a Protocol Defined Response (PDR) Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Week 12000
Week 24400
Week 36410
Week 48730
Week 96310
SecondaryMean Log10 Change From Baseline in HBV DNA Using Roche COBAS TaqMan - HPS Through Week 96 in Treated Participants

Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. HBV DNA log10 changes from baseline were summarized over time.

Time frame:
Baseline to Week 96
Reported as:
Mean · IU/mL
Mean Log10 Change From Baseline in HBV DNA Using Roche COBAS TaqMan - HPS Through Week 96 in Treated Participants
IU/mLLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Week 12-4.45 ± 0.2418-3.89 ± 0.1592-3.80 ± 0.4657
Week 24-5.30 ± 0.2744-4.85 ± 0.2900-3.89 ± 0.5440
Week 36-5.61 ± 0.2580-5.14 ± 0.2604-3.90 ± 0.2499
Week 48-5.86 ± 0.2176-5.36 ± 0.3032-4.32 ± 0.4794
Week 96-6.30 ± 0.2576-5.86 ± 0.2222-5.79 ± 0.5308
SecondaryAlanine Aminotransferase (ALT) Normalization From Baseline Through Week 96 in Treated Participants

Normalization in ALT= ALT ≤ 1.0\*upper limit of normal (ULN). Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Alanine Aminotransferase (ALT) Normalization From Baseline Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline012
Week 4112
Week 8322
Week 12573
Week 1815105
Week 2415125
Week 3016135
Week 3616165
Week 4216155
Week 4820184
Week 9610133
SecondaryNumber of Participants With HBV DNA by PCR Categories at Weeks 48 and 96 in Treated Participants

Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.

Time frame:
Baseline, Week 48, Week 96
Reported as:
Number · participants
Number of Participants With HBV DNA by PCR Categories at Weeks 48 and 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline >=17,200 IU/mL24195
Week 48: < 50 IU/mL1490
Week 48: 50 - < 172 IU/mL120
Week 48: 172 - < 1720 IU/mL331
Week 48: 1720 - < 17,200 IU/mL313
Week 48: > = 17,200 IU/mL131
Week 96: < 50 IU/mL8112
Week 96: 50 - < 172 IU/mL110
Week 96: 172 - < 1720 IU/mL301
Week 96: 1720 - < 17,200 IU/mL011
Week 96: > = 17,200 IU/mL000
SecondaryNumber of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants

Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12000
Week 241030
Week 361140
Week 481390
Week 967112
SecondaryNumber of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Plus HBeAg Seroconversion Through Week 96 in Treated Participants

Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion was determination of presence of HBeAb and loss of HBeAg. The method used for the detection of HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Plus HBeAg Seroconversion Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12000
Week 24400
Week 36410
Week 48830
Week 96310
SecondaryNumber of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Without HBeAg Seroconversion, Through Week 96 in Treated Participants

Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HBeAb. The method used for the detection of HBeAg/Ab serologies was the DiaSorin enzyme immunoassay kit.

Time frame:
Baseline to Week 96
Reported as:
Number · participants
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Without HBeAg Seroconversion, Through Week 96 in Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Baseline000
Week 12000
Week 24630
Week 36730
Week 48560
Week 964102
SecondaryNumber of Participants With Hematology Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants

Toxicity Scale: Division of AIDs (DAIDS) grades Version 1.0. Upper limit of normal (ULN); lower limit of normal (LLN); Cells per Liter (c/L); cells per microliter (c/µL); grams per deciliter (g/dL); milliequivalents per liter (mEq/L); cells per microliter (c/µL): Grade (Gr). Hemoglobin g/dL: Gr1:10.0-10.9;Gr2: 9.0-9.9; Gr3:7.0-8.9; Gr4: \<7.0. International normalization ratio (INR): Gr1:1.1-\<1.5\*ULN; Gr2: 1.6-\<2.0\*ULN; Gr3: 2.1-3.0\*ULN;Gr4: \>3.0\*ULN. Neutrophils/bands c/µL: Gr1;1.0-1.3\*10\^3; Gr2: 0.75-0.99\*10\^3; Gr 3: 0.50-0.749\*10\^3; Gr4: \<0.5\*10\^3.

Time frame:
Day 1 to Week 120
Reported as:
Number · participants
Number of Participants With Hematology Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Hemoglobin101
International normalization ratio430
Neutrophils (absolute) + bands330
SecondaryNumber of Participants With Chemistry Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants

Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO). Grade (Gr). ALT: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0 \*ULN; Gr3: 5.1-10.0\*ULN; Gr4:\>10.0\*ULN. Aspartate aminotransferase (AST): Gr1: 1.25-\<2.5\*ULN; Gr2:2.6-\<5.0\*ULN; Gr 3: 5.1-10.0\*ULN; Gr4\>10.0\*ULN. Alkaline phosphatase: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0\*ULN; Gr3: 5.1-10.0\*ULN; Gr4: \>10.0\*ULN. Lipase: Gr1:1.1-\<1.5\*ULN;Gr2:1.6-\<3.0\*ULN; Gr3: 3.1-5.0\*ULN; Gr4: \>5.0\*ULN. Creatinine: Gr1: 1.1-1.3\*ULN; Gr2: 1.4-\<1.8\*ULN; Gr3: 1.9 - \<3.4\*ULN; Gr4: \>=3.5\*ULN. Glucose mg/dL (high): Gr1:110-\<125 (Fasting)/116-\<160;Gr2:126-\<250 (F)/161-\<250; Gr3: 251-500; Gr4: \>500.Glucose (low): Gr1: 55-64; Gr2: 40 - \<54; Gr3: 30-39; Gr4: \<30 mg/dL.

Time frame:
Day 1 to Week 120
Reported as:
Number · participants
Number of Participants With Chemistry Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
ALT23174
AST1491
Alkaline Phosphatase330
Lipase5123
Creatinine110
Glucose, high341
Glucose, low341
SecondaryNumber of Participants With Electrolyte Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants

Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO) for chloride. Milliequivalents per liter (mEq/L); Grade (Gr). Chloride high (mEq/L): Gr1: 113-\<117; Gr2: 117-\<121; Gr3: 121-125; Gr4: \>125. Potassium low (mEq/L): Gr1: 3.0-3.4; Gr2: 2.5-2.9; Gr3:2.0-\<2.4; Gr4: \<2.0. Potassium high: Gr1; 5.6- \<6.0; Gr2: 6.1-\<6.5; Gr3: 6.6-7.0; Gr4: \>7.0. Sodium high (mEq/L): Gr1; 146-\<150; Gr2: 151-\<154; Gr3: 155-\<159; Gr4: \>=160.

Time frame:
Day 1 Week 120
Reported as:
Number · participants
Number of Participants With Electrolyte Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
participantsLamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)
Chloride, high300
Potassium, low100
Potassium, high110
Sodium, high430

Adverse events

Collected over From first dose to date of last dose plus 5 days, up to 120 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A LVD-naive0/24 (0%)2/24 (8.3%)21/24 (87.5%)
Group B LVD-exp0/19 (0%)0/19 (0%)17/19 (89.5%)
Group C NA-exp0/5 (0%)0/5 (0%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventGroup A LVD-naiveGroup B LVD-expGroup C NA-exp
GastroenteritisInfections and infestations1/240/190/5
PneumoniaInfections and infestations1/240/190/5
Alanine aminotransferase increasedInvestigations1/240/190/5
Aspartate aminotransferase increasedInvestigations1/240/190/5
Most frequent other events
Showing 10 of 65
Most frequent other events
EventGroup A LVD-naiveGroup B LVD-expGroup C NA-exp
Viral upper respiratory tract infectionInfections and infestations4/249/191/5
PyrexiaGeneral disorders10/245/191/5
Upper respiratory tract infectionInfections and infestations10/243/192/5
HeadacheNervous system disorders7/245/190/5
CoughRespiratory, thoracic and mediastinal disorders7/245/191/5
Abdominal painGastrointestinal disorders4/244/191/5
VomitingGastrointestinal disorders2/244/191/5
DiarrhoeaGastrointestinal disorders5/243/191/5
TinnitusEar and labyrinth disorders0/240/191/5
Ocular hyperaemiaEye disorders0/240/191/5

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Lamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)Total
Mean9.2 ± 5.4111.0 ± 4.428.8 ± 5.029.9 ± 4.98
Age, Customized
Age, Customized(participants)Lamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)Total
≥ 2 years to ≤ 6 years73212
>6 years to ≤ 12 years97218
>12 years to ≤18 years89118
Sex: Female, Male
Sex: Female, Male(Participants)Lamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)Total
Female147223
Male1012325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)Total
American Indian or Alaska Native0000
Asian1710532
Native Hawaiian or Other Pacific Islander0101
Black or African American0202
White56011
More than one race1001
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(participants)Lamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)Total
United States105116
Taiwan3003
Canada1001
Argentina3003
Belgium1102
Brazil1304
United Kingdom2103
Korea, Republic of39416
Hepatitis B virus (HBV) deoxyribonucleic acid (DNA)
Hepatitis B virus (HBV) deoxyribonucleic acid (DNA)(log10 IU/mL)Lamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)Total
Mean7.92 ± 0.8647.74 ± 0.8567.96 ± 0.2387.85 ± 0.812
Alanine Aminotransferase (ALT)
Alanine Aminotransferase (ALT)(U/L)Lamivudine (LVD)-Naive (Group A)Lamivudine (LVD)-Experienced (Group B)Nucleoside/Tide Analog (NA) - Experienced (Group C)Total
Mean142.8 ± 85.18125.7 ± 67.9644.6 ± 22.96125.8 ± 78.83
08

Study locations

19 sites
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Connecticut Children'S Medical Center
    Hartford, Connecticut 06106, United States
  • University Of Florida
    Gainesville, Florida 32610, United States
  • Johns Hopkins School Of Medicine
    Baltimore, Maryland 21287, United States
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
  • Mount Sinai School Of Medicine
    New York, New York 10029, United States
  • Children'S Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • University Of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Local Institution
    Buenos Aires, 1425, Argentina
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90035, Brazil
  • Local Institution
    Sco Paulo, Sao Paulo 05403, Brazil
  • Local Institution
    Toronto, Ontario M5G 1X8, Canada
  • Local Institution
    Seoul, 135-710, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
  • Local Institution
    Taipei, 100, Taiwan
  • Local Institution
    London, Greater London SE5 9RS, United Kingdom
  • Local Institution
    Birmingham, West Midlands B4 6NH, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2007 to primary completion in Aug 2013, 74 months.

Results were first posted in Aug 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2007
First posted
Jan 18, 2007
StartActual
Jun 30, 2007
Primary completionActual
Aug 31, 2013
CompletionActual
Sep 4, 2017
Results first posted
Aug 7, 2014
Last update
May 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00423891
Responsible party
Sponsor
First posted
Jan 18, 2007
Start date
Jun 30, 2007
Primary completion
Aug 31, 2013
Completion
Sep 4, 2017
Results posted
Aug 7, 2014
Last update
May 2, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion